Lupin Receives U.S. FDA Approval for Ranluspec™ (ranibizumab) Injection

The U.S. Food and Drug Administration (FDA) has approved Lupin's Ranluspec™ (ranibizumab-hkdz) as an interchangeable biosimilar referencing Lucentis®. This approval expands patient access to proven vision therapies for conditions such as neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. Ranluspec™ is the only interchangeable biosimilar ranibizumab approved in the U.S. in both vials and pre-filled syringes.